• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hims & Hers Health, Inc. Reports Second Quarter 2023 Financial Results and Raises Full Year 2023 Outlook

    8/7/23 4:15:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email

    Revenue of $207.9 million, up 83% year-over-year in Q2 2023

    Net loss of $7.2 million; Adjusted EBITDA profitability of $10.6 million in Q2 2023

    Subscribers grew to 1.3 million, up 74% year-over-year in Q2 2023

    Raises full year 2023 revenue guidance to a range of $830 million to $850 million and Adjusted EBITDA guidance to a range of $35 million to $40 million

    Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today reported financial results for the second quarter ended June 30, 2023.

    "This quarter marks a significant turning point for Hims & Hers, where step-change progress was made in transforming our company from an access-oriented company, towards a platform offering a personalized patient experience," said Andrew Dudum, co-founder and CEO. "The capabilities that we have spent years building allow us to offer unique and differentiated products across our current categories, as well as seamlessly enter new categories such as Cardiovascular Health and Weight Management. These are some of the most commonly occurring and emotionally resonant conditions, and by addressing them, we are one giant step closer towards having the ability to improve the life of every individual in the world."

    "We are excited by the progress made this quarter, which we believe sets that foundation for long-term growth at an attractive margin profile through distinct competitive advantages," said Yemi Okupe, CFO. "Our economic flywheel is clearly working. It has enabled us to strategically bring highly sought after personalized products to very attractive price points, and simultaneously expand margins. We believe this uniquely positions us for significant market share gains."

    Key Business Metrics

    (In Thousands, Except for Monthly Online Revenue per Average Subscriber and AOV, Unaudited)

     

     

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

    2022

     

    % Change

     

    2023

     

    2022

     

    % Change

    Subscribers (end of period)

     

     

    1,300

     

     

    748

     

    74

    %

     

     

    1,300

     

     

    748

     

    74

    %

    Monthly Online Revenue per Average Subscriber

     

    $

    53

     

    $

    51

     

    4

    %

     

    $

    55

     

    $

    52

     

    6

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net Orders

     

     

    2,109

     

     

    1,385

     

    52

    %

     

     

    4,156

     

     

    2,592

     

    60

    %

    AOV

     

    $

    95

     

    $

    78

     

    22

    %

     

    $

    93

     

    $

    78

     

    19

    %

    Revenue

    (In Thousands, Unaudited)

     

     

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

    2022

     

    % Change

     

    2023

     

    2022

     

    % Change

    Online Revenue

     

    $

    201,178

     

    $

    107,462

     

    87

    %

     

    $

    385,353

     

    $

    201,564

     

    91

    %

    Wholesale Revenue

     

     

    6,734

     

     

    6,101

     

    10

    %

     

     

    13,329

     

     

    13,313

     

    —

    %

    Total revenue

     

    $

    207,912

     

    $

    113,563

     

    83

    %

     

    $

    398,682

     

    $

    214,877

     

    86

    %

    Second Quarter 2023 Financial Highlights

    • Revenue was $207.9 million for the second quarter of 2023 compared to $113.6 million for the second quarter of 2022, an increase of 83% year-over-year.
    • Gross margin was 82% for the second quarter of 2023 compared to 77% for the second quarter of 2022.
    • Net loss was $(7.2) million for the second quarter of 2023 compared to $(19.7) million for the second quarter of 2022.
    • Adjusted EBITDA was $10.6 million for the second quarter of 2023 compared to $(7.5) million for the second quarter of 2022.

    A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net loss, its most comparable financial measure under generally accepted accounting principles in the United States ("U.S. GAAP"), has been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA is also included below under the heading "Non-GAAP Financial Measures".

    Financial Outlook

    Hims & Hers is providing the following guidance:

    For the third quarter 2023, we expect:

    • Revenue of $217 million to $222 million.
    • Adjusted EBITDA of $10 million to $13 million, reflecting an Adjusted EBITDA margin of 5% to 6%.

    For the full year 2023, we expect:

    • Revenue of $830 million to $850 million.
    • Adjusted EBITDA of $35 million to $40 million, reflecting an Adjusted EBITDA margin of 4% to 5%.

    The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the "Cautionary Note Regarding Forward-Looking Statements" safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

    We have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net loss. See "Non-GAAP Financial Measures" for additional important information regarding Adjusted EBITDA.

    Conference Call

    Hims & Hers will host a conference call to review the second quarter 2023 results on August 7, 2023, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at https://investors.forhims.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

    About Hims & Hers Health, Inc.

    Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

    We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

    For more information, please visit https://investors.forhims.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believe," "estimate," "anticipate," "expect," "assume," "imply," "intend," "plan," "may," "will," "potential," "project," "predict," "continue," "could," or "should," or, in each case, their plural, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line growth and profitability and our ability to attain our long-term financial targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our financial condition, results of operations, short- and long-term business operations, objectives, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions, changes in our product or offering mix, the timing and market acceptance of any new products or offerings, the success of our business model, our market opportunity, our ability to scale our business, the growth of certain of our categories, our ability to innovate on and expand the scope of our offerings and experiences, our ability to reinvest into the customer experience, and our ability to comply with the extensive, complex and evolving regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations. These statements are based on management's current expectations, but actual results may differ materially due to various factors.

    The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the "Risk Factors" section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the "Commission").

    Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

    By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-K, our most recently filed Quarterly Report on Form 10-Q, and any of our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

    Key Business Metrics

    "Online Revenue" represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them.

    "Wholesale Revenue" represents non-prescription product sales to retailers through wholesale purchasing agreements. We sell only non-prescription products to wholesale partners. In addition to being revenue generative and profitable, wholesale partnerships have the added benefit of generating brand awareness with new customers in physical environments.

    "Subscribers" are customers who have one or more "Subscriptions", which are agreements pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of months (for example, billed every month or every three months), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel Subscriptions in between billing periods to stop receiving additional products and services and can reactivate Subscriptions to continue receiving additional products and services.

    "Monthly Online Revenue per Average Subscriber" is defined as Online Revenue divided by "Average Subscribers", which amount is then further divided by the number of months in a period. "Average Subscribers" are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

    "Net Orders" are defined as the number of online customer orders minus transactions related to refunds, credits, chargebacks, and other negative adjustments. Net Orders represent transactions made on our platform during a defined period of time and exclude revenue recognition adjustments recorded pursuant to U.S. GAAP.

    Average Order Value ("AOV") is defined as Online Revenue divided by Net Orders.

     

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In Thousands, Except Share and Per Share Data, Unaudited)

     

     

    June 30, 2023

     

    December 31, 2022

     

    (Unaudited)

     

     

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    65,417

     

     

    $

    46,772

     

    Short-term investments

     

    127,725

     

     

     

    132,853

     

    Inventory

     

    21,417

     

     

     

    21,562

     

    Prepaid expenses and other current assets

     

    20,089

     

     

     

    15,408

     

    Total current assets

     

    234,648

     

     

     

    216,595

     

    Restricted cash

     

    856

     

     

     

    856

     

    Goodwill

     

    110,881

     

     

     

    110,881

     

    Intangibles, net

     

    19,962

     

     

     

    21,841

     

    Operating lease right-of-use assets

     

    4,735

     

     

     

    4,936

     

    Other long-term assets

     

    18,802

     

     

     

    11,232

     

    Total assets

    $

    389,884

     

     

    $

    366,341

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    38,267

     

     

    $

    32,363

     

    Accrued liabilities

     

    19,607

     

     

     

    12,448

     

    Deferred revenue

     

    2,058

     

     

     

    1,472

     

    Earn-out liabilities

     

    4,776

     

     

     

    —

     

    Operating lease liabilities

     

    1,839

     

     

     

    1,658

     

    Total current liabilities

     

    66,547

     

     

     

    47,941

     

    Operating lease liabilities

     

    3,252

     

     

     

    3,649

     

    Earn-out liabilities

     

    —

     

     

     

    2,975

     

    Other long-term liabilities

     

    14

     

     

     

    35

     

    Total liabilities

     

    69,813

     

     

     

    54,600

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 202,419,498 and 200,051,689 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of June 30, 2023 and December 31, 2022

     

    21

     

     

     

    21

     

    Additional paid-in capital

     

    682,161

     

     

     

    656,626

     

    Accumulated other comprehensive loss

     

    (258

    )

     

     

    (277

    )

    Accumulated deficit

     

    (361,853

    )

     

     

    (344,629

    )

    Total stockholders' equity

     

    320,071

     

     

     

    311,741

     

    Total liabilities and stockholders' equity

    $

    389,884

     

     

    $

    366,341

     

     

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (In Thousands, Except Share and Per Share Data, Unaudited)

     

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Revenue

    $

    207,912

     

     

    $

    113,563

     

     

    $

    398,682

     

     

    $

    214,877

     

    Cost of revenue

     

    37,754

     

     

     

    26,387

     

     

     

    75,099

     

     

     

    52,945

     

    Gross profit

     

    170,158

     

     

     

    87,176

     

     

     

    323,583

     

     

     

    161,932

     

    Gross margin %

     

    82

    %

     

     

    77

    %

     

     

    81

    %

     

     

    75

    %

    Operating expenses:(1)

     

     

     

     

     

     

     

    Marketing

     

    107,219

     

     

     

    60,490

     

     

     

    204,464

     

     

     

    108,583

     

    Operations and support

     

    29,227

     

     

     

    17,448

     

     

     

    55,409

     

     

     

    33,131

     

    Technology and development

     

    11,804

     

     

     

    6,861

     

     

     

    22,552

     

     

     

    12,949

     

    General and administrative

     

    31,144

     

     

     

    22,567

     

     

     

    61,657

     

     

     

    44,378

     

    Total operating expenses

     

    179,394

     

     

     

    107,366

     

     

     

    344,082

     

     

     

    199,041

     

    Loss from operations

     

    (9,236

    )

     

     

    (20,190

    )

     

     

    (20,499

    )

     

     

    (37,109

    )

    Other income:

     

     

     

     

     

     

     

    Change in fair value of liabilities

     

    (173

    )

     

     

    121

     

     

     

    (468

    )

     

     

    562

     

    Other income, net

     

    2,239

     

     

     

    402

     

     

     

    4,116

     

     

     

    722

     

    Total other income, net

     

    2,066

     

     

     

    523

     

     

     

    3,648

     

     

     

    1,284

     

    Loss before income taxes

     

    (7,170

    )

     

     

    (19,667

    )

     

     

    (16,851

    )

     

     

    (35,825

    )

    Benefit (provision) for income taxes

     

    13

     

     

     

    (12

    )

     

     

    (373

    )

     

     

    (106

    )

    Net loss

     

    (7,157

    )

     

     

    (19,679

    )

     

     

    (17,224

    )

     

     

    (35,931

    )

    Other comprehensive (loss) income

     

    (147

    )

     

     

    (145

    )

     

     

    19

     

     

     

    (331

    )

    Total comprehensive loss

    $

    (7,304

    )

     

    $

    (19,824

    )

     

    $

    (17,205

    )

     

    $

    (36,262

    )

    Net loss per share attributable to common stockholders:

     

     

     

     

     

     

     

    Basic and diluted

    $

    (0.03

    )

     

    $

    (0.10

    )

     

    $

    (0.08

    )

     

    $

    (0.18

    )

    Weighted average shares outstanding:

     

     

     

     

     

     

     

    Basic and diluted

     

    208,422,825

     

     

     

    203,949,535

     

     

     

    207,785,104

     

     

     

    203,326,215

     

    ______________

    (1)

    Includes stock-based compensation expense as follows (in thousands):

     

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

    2022

     

    2023

     

    2022

    Marketing

     

    $

    1,487

     

    $

    1,072

     

    $

    2,483

     

    $

    1,895

    Operations and support

     

     

    1,854

     

     

    667

     

     

    3,008

     

     

    1,153

    Technology and development

     

     

    2,092

     

     

    1,090

     

     

    3,553

     

     

    1,996

    General and administrative

     

     

    11,412

     

     

    7,803

     

     

    21,968

     

     

    14,444

    Total stock-based compensation expense

     

    $

    16,845

     

    $

    10,632

     

    $

    31,012

     

    $

    19,488

     

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In Thousands, Unaudited)

     

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

    Operating activities

     

     

     

    Net loss

    $

    (17,224

    )

     

    $

    (35,931

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

    Depreciation and amortization

     

    4,494

     

     

     

    3,562

     

    Stock-based compensation

     

    31,012

     

     

     

    19,488

     

    Change in fair value of liabilities

     

    468

     

     

     

    (562

    )

    Net (accretion) amortization on securities

     

    (2,517

    )

     

     

    863

     

    Benefit for deferred taxes

     

    (20

    )

     

     

    (258

    )

    Impairment of long-lived assets

     

    429

     

     

     

    —

     

    Non-cash operating lease cost

     

    914

     

     

     

    755

     

    Non-cash acquisition-related costs

     

    1,066

     

     

     

    58

     

    Non-cash other

     

    75

     

     

     

    —

     

    Changes in operating assets and liabilities:

     

     

     

    Inventory

     

    145

     

     

     

    (6,115

    )

    Prepaid expenses and other current assets

     

    (4,756

    )

     

     

    (6,762

    )

    Other long-term assets

     

    (32

    )

     

     

    (27

    )

    Accounts payable

     

    5,438

     

     

     

    7,453

     

    Accrued liabilities

     

    7,159

     

     

     

    150

     

    Deferred revenue

     

    586

     

     

     

    (851

    )

    Operating lease liabilities

     

    (928

    )

     

     

    (772

    )

    Earn-out payable

     

    —

     

     

     

    (6,848

    )

    Net cash provided by (used in) operating activities

     

    26,309

     

     

     

    (25,797

    )

    Investing activities

     

     

     

    Purchases of investments

     

    (65,376

    )

     

     

    (89,146

    )

    Maturities of investments

     

    72,334

     

     

     

    101,259

     

    Proceeds from sales of investments

     

    676

     

     

     

    22,291

     

    Investment in website and mobile application development and internal-use software

     

    (4,062

    )

     

     

    (2,397

    )

    Purchases of property, equipment, and intangible assets

     

    (5,312

    )

     

     

    (276

    )

    Deferred consideration paid for acquisitions

     

    —

     

     

     

    (459

    )

    Net cash (used in) provided by investing activities

     

    (1,740

    )

     

     

    31,272

     

    Financing activities

     

     

     

    Proceeds from exercise of vested stock options

     

    560

     

     

     

    1,470

     

    Payments for taxes related to net share settlement of equity awards

     

    (7,411

    )

     

     

    (1,183

    )

    Proceeds from employee stock purchase plan

     

    898

     

     

     

    553

     

    Payments for earn-out consideration for acquisitions

     

    —

     

     

     

    (23,014

    )

    Net cash used in financing activities

     

    (5,953

    )

     

     

    (22,174

    )

    Foreign currency effect on cash and cash equivalents

     

    29

     

     

     

    (52

    )

    Increase (decrease) in cash, cash equivalents, and restricted cash

     

    18,645

     

     

     

    (16,751

    )

    Cash, cash equivalents, and restricted cash at beginning of period

     

    47,628

     

     

     

    72,640

     

    Cash, cash equivalents, and restricted cash at end of period

    $

    66,273

     

     

    $

    55,889

     

    Reconciliation of cash, cash equivalents, and restricted cash

     

     

     

    Cash and cash equivalents

    $

    65,417

     

     

    $

    55,033

     

    Restricted cash

     

    856

     

     

     

    856

     

    Total cash, cash equivalents, and restricted cash

    $

    66,273

     

     

    $

    55,889

     

    Supplemental disclosures of cash flow information

     

     

     

    Cash paid for taxes

    $

    626

     

     

    $

    528

     

    Non-cash investing and financing activities

     

     

     

    Purchase of property and equipment included in accounts payable

    $

    466

     

     

    $

    —

     

    Right-of-use asset obtained in exchange for lease liability

     

    591

     

     

     

    —

     

    Vesting of early exercised stock options

     

    —

     

     

     

    76

     

     

    Non-GAAP Financial Measures

    In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), and Adjusted EBITDA margin (which is a non-GAAP ratio), each as defined below. We use Adjusted EBITDA and Adjusted EBITDA margin to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA and Adjusted EBITDA margin, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA and Adjusted EBITDA margin to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA and Adjusted EBITDA margin is helpful to our investors as they are used by management in assessing the health of our business and our operating performance.

    However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA or Adjusted EBITDA margin as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

    Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. "Adjusted EBITDA" is defined as net loss before stock-based compensation, depreciation and amortization, acquisition-related costs (which includes consideration paid for employee compensation with vesting requirements incurred directly as a result of acquisitions, inclusive of revaluation of earn-out consideration recorded in general and administrative expenses), change in fair value of liabilities, impairment of long-lived assets, income taxes, and interest income. "Adjusted EBITDA margin" is defined as Adjusted EBITDA divided by revenue.

    Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net loss and other U.S. GAAP results.

     

    Net Loss to Adjusted EBITDA Reconciliation

    (In Thousands, Unaudited)

     

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

    2023

     

    2022

     

    2023

     

    2022

     

     

     

     

     

     

     

     

    Revenue

    $

    207,912

     

     

    $

    113,563

     

     

    $

    398,682

     

     

    $

    214,877

     

     

     

     

     

     

     

     

     

    Net loss

     

    (7,157

    )

     

     

    (19,679

    )

     

     

    (17,224

    )

     

     

    (35,931

    )

    Stock-based compensation

     

    16,845

     

     

     

    10,632

     

     

     

    31,012

     

     

     

    19,488

     

    Depreciation and amortization

     

    2,377

     

     

     

    1,821

     

     

     

    4,494

     

     

     

    3,562

     

    Acquisition-related costs

     

    583

     

     

     

    150

     

     

     

    1,229

     

     

     

    266

     

    Change in fair value of liabilities

     

    173

     

     

     

    (121

    )

     

     

    468

     

     

     

    (562

    )

    Impairment of long-lived assets

     

    —

     

     

     

    —

     

     

     

    429

     

     

     

    —

     

    (Benefit) provision for income taxes

     

    (13

    )

     

     

    12

     

     

     

    373

     

     

     

    106

     

    Interest income

     

    (2,173

    )

     

     

    (356

    )

     

     

    (4,086

    )

     

     

    (531

    )

    Adjusted EBITDA

    $

    10,635

     

     

    $

    (7,541

    )

     

    $

    16,695

     

     

    $

    (13,602

    )

     

     

     

     

     

     

     

     

    Net loss as a % of revenue

     

    (3

    )%

     

     

    (17

    )%

     

     

    (4

    )%

     

     

    (17

    )%

    Adjusted EBITDA margin

     

    5

    %

     

     

    (7

    )%

     

     

    4

    %

     

     

    (6

    )%

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230807545114/en/

    Get the next $HIMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    3/10/2026$24.00Sell → Neutral
    Citigroup
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    3/9/2026$30.00Hold → Buy
    Needham
    2/24/2026Buy → Neutral
    BTIG Research
    1/12/2026$33.00In-line
    Evercore ISI
    12/9/2025$48.00Overweight
    Barclays
    10/21/2025Sector Weight
    KeyBanc Capital Markets
    6/23/2025Buy → Hold
    Needham
    More analyst ratings

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Hims & Hers Health Inc.

    SCHEDULE 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    3/27/26 9:32:32 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 8-K filed by Hims & Hers Health Inc.

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    3/11/26 5:21:18 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Hims & Hers Health Inc.

    SCHEDULE 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    3/5/26 11:49:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Novo Nordisk's FDA-Approved GLP-1s Now Available With Hims & Hers

    Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill Hims & Hers Health, Inc. (NYSE:HIMS) today announced that a broad assortment of Novo Nordisk's FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill.1 As a part of a collaboration with Novo Nordisk, Hims & Hers is making it simpler for customers to access FDA-approved GLP-1 medications which are now available at more affordable prices, with more doses and delivery methods. This expansion makes Hims & Hers the largest global consumer health platform for af

    3/26/26 12:00:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers

    The program debuts with Prenuvo and Eight Sleep, providing discounts on advanced diagnostics and sleep technology Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best innovations in whole body health. This new initiative provides active subscribers access to discounts from health partners, all in one place, including whole body MRI scans from Prenuvo and adaptive bed systems from Eight Sleep. This is just the beginning of a larger benefits program that will make comprehensive, holistic care more accessible and affordable for subscribers. "True health doesn't happen in a vacuum.

    3/10/26 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by Citigroup with a new price target

    Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

    3/10/26 8:37:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Hims & Hers Health from Underperform to Neutral and set a new price target of $23.00

    3/10/26 8:37:14 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by Needham with a new price target

    Needham upgraded Hims & Hers Health from Hold to Buy and set a new price target of $30.00

    3/9/26 11:28:34 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Okupe Oluyemi

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/24/26 6:09:57 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Becklund Irene

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/18/26 4:17:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chi Michael

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/18/26 4:17:34 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Financials

    Live finance-specific insights

    View All

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the c

    2/2/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results

    Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 million, up 21% year-over-year in Q3 2025 Narrows full year 2025 revenue guidance to $2.335 billion to $2.355 billion and Adjusted EBITDA guidance to $307 million to $317 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a shareholder letter that is posted at investors.hims.com. "This quarter we continued to prove that our vision of helping tens of mill

    11/3/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 12:09:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company's global public policy, regulatory, and government affairs functions. A former senior leader at the FDA, prosecutor f

    11/17/25 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care